Zealand Pharma A/S (0NZU.IL)
| Previous close | 348.90 |
| Open | 353.40 |
| Bid | 348.40 x 0 |
| Ask | 367.20 x 0 |
| Day's range | 351.80 - 360.80 |
| 52-week range | 189.80 - 366.00 |
| Volume | |
| Avg. volume | 57,335 |
| Market cap | 21.364B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -15.13 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 44 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 7, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securi
- GlobeNewswire
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 43 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, December 7, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 47,077 divided into 47,077 new shares with a nominal value of DKK 1 each. The inc
- GlobeNewswire
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and clinical experts Copenhagen, Denmark, December 4, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines is hosting an Obesity R&D Event in London on Tuesday, December 5th (1:3
